BioSpace reports that the European Medicines Agency (EMA) has accepted a filing from Pfizer for regulatory review of axitinib for patients with advanced renal cell carcinoma (RCC) following failure of prior systemic treatment.

The submission made by the company was based on phase III data from the AXIS 1032 trial. BioSpace notes that the results of this trial are due to be presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO).